Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-23-001428
Filing Date
2023-01-04
Accepted
2023-01-04 19:39:43
Documents
2
Period of Report
2023-01-04

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1583
2 POA DOCUMENT poa.txt EX-24 3531
  Complete submission text file 0001209191-23-001428.txt   6465
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Issuer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD. #900 SOUTH SAN FRANCISCO CA 94080
Business Address
Porter Derrell (Reporting) CIK: 0001706400 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40551 | Film No.: 23509201